Deep Tech Catalyst · Jun 2026
Profiles Signatur Biosciences’ DTC Bio-supported work broadening PCRchitectur from a single lead product to a wider precision-diagnostics platform.
Simple tests for complex diseases.
Company research
Public company, workplace, funding, and market signals
Overview
Signatur Biosciences is a London-headquartered biotech spinout founded in 2022 that is building PCRchitectur, a platform that lets standard qPCR machines run decentralized molecular diagnostics, starting with breast cancer prognosis.
Primary product
OncoSignatur Breast (OSB), a qPCR-based breast cancer prognostic test kit powered by PCRchitectur
Founded
2022
Headquarters
London, United Kingdom
Team size
11-50
Work style
Remote
Industry
Biotechnology Research
Sub-industry
Molecular diagnostics
Offices
London, United Kingdom
Open Positions
0 jobs at Signatur Biosciences
No open positions
Check back later for new openings